MyFinsight
Home
Blog
About
Contact
Download
Download image
Total revenues
$3,221,253K
(12.87%↑ Y/Y)
Net income
$348,901K
(-18.26%↓ Y/Y)
Acquired in-process
research & development...
$220,963K
Stock-based compensation
$181,409K
(-10.00%↓ Y/Y)
Impairment of assets
$125,012K
Canceled cashflow
$2,872,352K
Roctavian inventory
write-off
$119,208K
Depreciation and
amortization
$79,557K
(-17.49%↓ Y/Y)
Accounts payable and
accrued liabilities
$66,136K
(305.14%↑ Y/Y)
Deferred income taxes
$48,738K
(-13.12%↓ Y/Y)
Other long-term
liabilities
$14,869K
(0.73%↑ Y/Y)
Other current assets
-$8,891K
(-335.34%↓ Y/Y)
Unrealized foreign
exchange gain
-$4,459K
(-126.62%↓ Y/Y)
Non-cash interest
expense
$2,622K
(-21.94%↓ Y/Y)
Net cash provided by
operating activities
$827,994K
(44.54%↑ Y/Y)
Canceled cashflow
$392,771K
Cost of sales
$717,442K
(23.65%↑ Y/Y)
G&a expenses
$622,861K
(17.02%↑ Y/Y)
S&m expenses
$530,156K
(11.20%↑ Y/Y)
Research and
development-Research And Early...
$383,705K
(-11.59%↓ Y/Y)
Research and
development-Later Stage Clinical...
$308,334K
(1017.92%↑ Y/Y)
Research and
development-Marketed Products
$229,891K
(-19.50%↓ Y/Y)
Other segment
expense, net
$79,963K
(-11.75%↓ Y/Y)
Net increase in cash
and cash...
$368,837K
(96.49%↑ Y/Y)
Canceled cashflow
$459,157K
Accounts receivable, net
$228,054K
(293.81%↑ Y/Y)
Inventory
$116,929K
(84.05%↑ Y/Y)
Other assets
$38,573K
(-47.66%↓ Y/Y)
Accretion of discount on
investments
$4,801K
(-42.47%↓ Y/Y)
Other
$4,414K
(121.92%↑ Y/Y)
Maturities and sales of
investments
$337,801K
(-46.64%↓ Y/Y)
Proceeds from exercises
of awards under...
$14,460K
(-70.66%↓ Y/Y)
Net cash provided by
(used in) investing...
-$414,242K
(-403.49%↓ Y/Y)
Net cash used in
financing activities
-$42,394K
(91.95%↑ Y/Y)
Effect of exchange rate
changes on cash
-$2,521K
(-152.19%↓ Y/Y)
Canceled cashflow
$337,801K
Canceled cashflow
$14,460K
Purchases of investments
$355,875K
(-13.25%↓ Y/Y)
Acquisition, net of cash
acquired
$285,193K
Taxes paid related to
net share...
$55,965K
(-27.84%↓ Y/Y)
Purchases of property,
plant and equipment
$103,038K
(20.62%↑ Y/Y)
Purchase of intangible
assets
$7,937K
(-33.83%↓ Y/Y)
Other
-$889K
(72.02%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
biomarin-logo-svg
BMRN
biomarin-logo-svg
BMRN